Chemistry:VSN16R
From HandWiki
VSN16R (SPG601) is a drug which acts as an opener of BKCa large-conductance, calcium-activated potassium channels. It is similar in chemical structure to some cannabinoid derivatives such as methanandamide and CB-86, and was originally thought to be an atypical cannabinoid compound, but pharmacological studies showed it to be inactive at both cannabinoid receptors and related receptors such as GPR55, and eventually it was found to be a selective BKCa channel opener. It has neuroprotective effects and reduces muscle spasticity, and is being researched as a potential therapeutic agent for the treatment of Fragile X syndrome.[1][2][3][4][5]
See also
- Flindokalner
References
- ↑ "Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat". British Journal of Pharmacology 152 (5): 751–764. November 2007. doi:10.1038/sj.bjp.0707470. PMID 17891160.
- ↑ "Big conductance calcium-activated potassium channel openers control spasticity without sedation". British Journal of Pharmacology 174 (16): 2662–2681. August 2017. doi:10.1111/bph.13889. PMID 28677901.
- ↑ "The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca2+-Activated K+ Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing". Pharmaceuticals (Basel, Switzerland) 12 (3): 104. July 2019. doi:10.3390/ph12030104. PMID 31277369.
- ↑ "Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels". Pharmaceuticals (Basel, Switzerland) 16 (7): 972. July 2023. doi:10.3390/ph16070972. PMID 37513884.
- ↑ "SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study". Scientific Reports 16 (1). April 2026. doi:10.1038/s41598-026-46928-6. PMID 41946887. Bibcode: 2026NatSR..1611705P.
 |  |
